Prevention of Vein Graft Failure
预防静脉移植失败
基本信息
- 批准号:8039215
- 负责人:
- 金额:$ 42.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-04-01 至 2013-12-18
- 项目状态:已结题
- 来源:
- 关键词:ActinsArginineAutologousBiochemistryBlood VesselsBypassCell Surface ReceptorsCellsChargeClinicalCytoskeletonDepositionDevelopmentDrug Delivery SystemsEngineeringEnvironmentEventExtracellular MatrixGoalsHSPB1 geneHeat shock proteinsHeparinHumanHyperplasiaInvestigationLeadMAPK14 geneMapsMass Spectrum AnalysisModelingMolecularMolecular Mechanisms of ActionMorphologyMuscle functionMyofibroblastOrgan Culture TechniquesOryctolagus cuniculusPeptidesPeripheralPhenotypePhosphorylationPhosphotransferasesPhysiologyPreventionProcessProductionProsthesisProtein EngineeringProteinsReceptor SignalingSaphenous VeinSmooth MuscleSmooth Muscle MyocytesStress FibersTechniquesTherapeuticVascular Smooth MuscleVeinsdesigndrug developmentgraft failurein vivoinhibitor/antagonistmigrationmimeticsnovelnovel therapeuticspreventprotein protein interactionresponse to injurytherapeutic targettool
项目摘要
DESCRIPTION (provided by applicant): Approximately 1,000,000 aortocoronary and peripheral vascular revascularizations are performed using autologous conduits. The leading cause of graft failure is the subsequent development of intimal hyperplasia. Intimal hyperplasia represents a response to injury that involves smooth muscle proliferation, migration, phenotypic modulation, and extracellular matrix (ECM) deposition. This proposal will develop a cell permeant peptide therapeutic to enhance graft patency by preventing the events that lead to intimal hyperplasia. A small heat shock protein, HSP27, is phosphorylated by a kinase cascade involving p38 map kinase and MAPKAP kinase II (MK2). Phosphorylated HSP27 is associated with the formation of actin stress fibers (myofibroblast phenotype) and enhanced smooth muscle migration. We have developed a cell permeant peptide that inhibits MK2. This peptide also inhibits stress fiber formation and ECM production. The specific aims of this proposal are: Specific aim #1: Determine the effect of transducible peptides which inhibit the phosphorylation of HSP27 on smooth muscle physiology, morphology, and biochemistry: We will determine the effect of the novel MK2 inhibitor peptide on intact human vascular smooth muscle segments and cultured vascular smooth muscle cells. Specific aim #2: Determine the effect of optimized peptide mimetics on intimal hyperplasia. We will first determine the effect of the MK2 inhibitor on intimal hyperplasia in a human saphenous vein graft organ culture model. Subsequently, we will determine the effect of the mimetics in vivo in a rabbit carotid interposition model. Specific aim #3: Determine the molecular mechanisms by which phosphorylated HSP27 "stabilizes" the actin cytoskeleton: We will use quantitative, high throughput mass spectrometry techniques to analyze the molecular associations of phosphorylated and nonphosphorylated HSP27. The goal of this project is to engineer biomolecules that enhance graft patency using protein transduction domains to directly introduce peptides into smooth muscle cells. Autologous conduits represent an ideal target for this therapeutic approach in that the graft can be treated ex vivo, thus providing an optimal environment for the delivery of engineered protein/peptide therapeutics. The molecules designed in this proposal represent novel therapeutics in that the usual targets of drug development (cell surface receptors and signaling cascades) are "bypassed" and protein-protein interactions are stoichiometrically altered by changing the phosphorylation of downstream target effector proteins (HSP27).
描述(由申请人提供):使用自体导管进行了约1,000,000例冠状动脉和外周血管血运重建。移植物失败的主要原因是内膜增生的后续发展。内膜增生是对损伤的反应,涉及平滑肌增殖、迁移、表型调节和细胞外基质(ECM)沉积。该提案将开发一种细胞渗透肽治疗剂,通过预防导致内膜增生的事件来增强移植物通畅性。一种小的热休克蛋白HSP 27通过涉及p38 map激酶和MAPKAP激酶II(MK 2)的激酶级联反应被磷酸化。磷酸化HSP 27与肌动蛋白应力纤维(肌成纤维细胞表型)的形成和增强平滑肌迁移有关。我们已经开发了抑制MK2的细胞渗透肽。该肽还抑制应力纤维形成和ECM产生。具体目标#1:确定抑制HSP 27磷酸化的可转导肽对平滑肌生理学、形态学和生物化学的影响:我们将确定新型MK 2抑制剂肽对完整的人血管平滑肌节段和培养的血管平滑肌细胞的影响。具体目标#2:确定优化的肽模拟物对内膜增生的影响。我们将首先在人隐静脉移植器官培养模型中确定MK2抑制剂对内膜增生的影响。随后,我们将在兔颈动脉间置模型中确定模拟物的体内效果。具体目标3:确定磷酸化HSP 27“稳定”肌动蛋白细胞骨架的分子机制:我们将使用定量,高通量质谱技术来分析磷酸化和非磷酸化HSP 27的分子关联。该项目的目标是设计生物分子,利用蛋白质转导结构域直接将肽引入平滑肌细胞,以增强移植物的通畅性。自体导管代表了这种治疗方法的理想靶点,因为移植物可以离体处理,从而为工程蛋白/肽治疗剂的递送提供了最佳环境。在该提案中设计的分子代表了新的治疗方法,因为药物开发的通常靶点(细胞表面受体和信号级联)被“绕过”,并且通过改变下游靶效应蛋白(HSP 27)的磷酸化来化学计量地改变蛋白质-蛋白质相互作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Colleen M Brophy其他文献
Colleen M Brophy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Colleen M Brophy', 18)}}的其他基金
Cell permeant peptidomimetics to prevent delayed vasospasm and neurological deficits after subarachnoid hemorrhage
细胞渗透性肽模拟物可预防蛛网膜下腔出血后迟发性血管痉挛和神经功能缺损
- 批准号:
10384341 - 财政年份:2022
- 资助金额:
$ 42.2万 - 项目类别:
相似国自然基金
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
相似海外基金
Targeting protein arginine methylation in the 9p21.3 loss tumor microenvironment
9p21.3 缺失肿瘤微环境中的靶向蛋白精氨酸甲基化
- 批准号:
489995 - 财政年份:2023
- 资助金额:
$ 42.2万 - 项目类别:
Operating Grants
The role of protein arginine methyl transferase PRMT1 on myelin development
蛋白精氨酸甲基转移酶PRMT1对髓磷脂发育的作用
- 批准号:
23K14287 - 财政年份:2023
- 资助金额:
$ 42.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Normalizing arginine metabolism with sepiaptein for immunostimulatory-shift ofHER2+ breast cancer
使用 Sepiaptein 使精氨酸代谢正常化以实现 HER2 乳腺癌的免疫刺激转变
- 批准号:
10776256 - 财政年份:2023
- 资助金额:
$ 42.2万 - 项目类别:
Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)
精氨酸消耗联合铂类紫杉烷化疗对侵袭性变异前列腺癌 (AVPC) 的影响
- 批准号:
10715329 - 财政年份:2023
- 资助金额:
$ 42.2万 - 项目类别:
Understanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in Lymphoma
了解淋巴瘤对蛋白精氨酸甲基转移酶抑制剂的耐药机制
- 批准号:
10668754 - 财政年份:2023
- 资助金额:
$ 42.2万 - 项目类别:
Physiological function of arginine signaling:macropinocytosisand tumor immune evasion
精氨酸信号的生理功能:巨胞饮作用与肿瘤免疫逃避
- 批准号:
23H03317 - 财政年份:2023
- 资助金额:
$ 42.2万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Targeting protein arginine methylation in the 9p21.3 loss tumor microenvironment
9p21.3 缺失肿瘤微环境中的靶向蛋白精氨酸甲基化
- 批准号:
498862 - 财政年份:2023
- 资助金额:
$ 42.2万 - 项目类别:
Operating Grants
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
- 批准号:
10584689 - 财政年份:2023
- 资助金额:
$ 42.2万 - 项目类别:
Arginine methylation of the RNA helicase DDX5 in the regulation of RNA/DNA hybrids during the DNA damage response.
RNA 解旋酶 DDX5 的精氨酸甲基化在 DNA 损伤反应期间调节 RNA/DNA 杂交体中的作用。
- 批准号:
487619 - 财政年份:2023
- 资助金额:
$ 42.2万 - 项目类别:
Operating Grants
Regulation of and Target Recognition by Protein Arginine Methyltransferase 1 (PRMT1)
蛋白质精氨酸甲基转移酶 1 (PRMT1) 的调节和目标识别
- 批准号:
10653465 - 财政年份:2023
- 资助金额:
$ 42.2万 - 项目类别: